Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: ito s. Mol Cancer Res. 2020 Apr;18(4):632-643. doi: 10.1158/1541-7786.MCR-19-0391. Epub 2020 Jan 23. Mol Cancer Res. 2020. PMID: 31974290
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era.
Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Tsukune Y, et al. Among authors: ito s. Ann Hematol. 2016 Sep;95(9):1465-72. doi: 10.1007/s00277-016-2742-7. Epub 2016 Jun 30. Ann Hematol. 2016. PMID: 27358178
Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K, Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa H, Tsukamoto N. Saito A, et al. Among authors: ito s. Int J Hematol. 2017 Nov;106(5):681-690. doi: 10.1007/s12185-017-2297-y. Epub 2017 Jul 7. Int J Hematol. 2017. PMID: 28687991 Clinical Trial.
Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial.
Isoda A, Murayama K, Ito S, Kohara Y, Iino M, Miyazawa Y, Matsumoto M, Handa H, Imai Y, Ishiguro T, Izumita W, Kitano K, Hirabayashi Y, Nakazawa H, Ishida F, Mitsumori T, Kirito K, Chou T, Murakami H; Kanshinetsu Multiple Myeloma Study Group. Isoda A, et al. Among authors: ito s. Int J Hematol. 2018 Jul;108(1):39-46. doi: 10.1007/s12185-018-2448-9. Epub 2018 Mar 28. Int J Hematol. 2018. PMID: 29594921 Clinical Trial.
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: ito s. Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410677 Free PMC article.
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.
Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N. Kubo K, et al. Among authors: ito s. Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7. Int J Hematol. 2020. PMID: 31701481 Clinical Trial.
Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.
Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K; for collaborative Investigators. Imaizumi Y, et al. Among authors: ito s. Cancer Sci. 2020 Dec;111(12):4567-4580. doi: 10.1111/cas.14658. Epub 2020 Oct 21. Cancer Sci. 2020. PMID: 32976684 Free PMC article.
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Ishida T, et al. Among authors: ito s. Jpn J Clin Oncol. 2022 Dec 5;52(12):1446-1449. doi: 10.1093/jjco/hyac137. Jpn J Clin Oncol. 2022. PMID: 36073950 Free PMC article. Clinical Trial. No abstract available.
9,447 results